Biohaven Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.03.18	Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine (PR Newswire)
01.03.18	Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet (PR Newswire)
21.02.18	Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists (PR Newswire)
18.01.18	Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist (PR Newswire)
09.01.18	Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet (PR Newswire)
21.12.17	Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder (PR Newswire)
27.11.17	Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant (PR Newswire)
20.11.17	Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine (PR Newswire)
16.11.17	Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine (PR Newswire)
15.11.17	Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results (PR Newswire)
06.11.17	Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 (PR Newswire)
01.11.17	Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS) (PR Newswire)
30.10.17	Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute (PR Newswire)
25.10.17	Biohaven Adds Clifford Bechtold as Chief Operating Officer (PR Newswire)
24.10.17	Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder (PR Newswire)
02.10.17	Biohaven Reports Negative Data From Spinocerebellar Ataxia Phase 2/3 Trial (RTTNews)
02.10.17	Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial (PR Newswire)
18.09.17	FDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is MTFB (RTTNews)
15.09.17	Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate... (PR Newswire)
06.09.17	International Isotopes Inc. Announces Dr. Robert Atcher Has Joined The Company Board of Directors (PR Newswire)
14.08.17	Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results (PR Newswire)
07.08.17	Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 (PR Newswire)
04.08.17	Biohaven Appoints Julia P. Gregory to Board of Directors (PR Newswire)
31.07.17	Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine (PR Newswire)
24.07.17	Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine (PR Newswire)
18.07.17	PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology (PR Newswire)
13.07.17	Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs (PR Newswire)
06.07.17	Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome (PR Newswire)
23.06.17	Biohaven Added to Russell Microcap® Index (PR Newswire)
22.06.17	Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives (PR Newswire)
16.06.17	Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results (PR Newswire)
09.06.17	Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer (PR Newswire)
01.06.17	Latest IPO Opportunities Setting Up for a Remarkable 2017 (PR Newswire)
01.06.17	Latest IPO Opportunities Setting Up for a Remarkable 2017 (PR Newswire)
30.05.17	Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole (PR Newswire)
15.05.17	Biohaven: Trigriluzole Gets FDA Fast Track Designation For SCA - Quick Facts (RTTNews)
15.05.17	Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA (PR Newswire)
12.05.17	Biohaven Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
04.05.17	Biohaven Announces Pricing of Initial Public Offering of Common Shares (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.18	2.24 %	K V
Part Grp Hldg	1’323.00	1.85 %	K V
Roche Hldg G	270.20	1.24 %	K V
Givaudan	3’920.00	0.98 %	K V
Lonza Grp	561.40	0.68 %	K V
Geberit	502.60	-0.63 %	K V
CieFinRichemont	140.00	-0.67 %	K V
Zurich Insur Gr	542.20	-0.91 %	K V
Swiss Re	133.30	-1.11 %	K V
Kuehne+Nagel Int	201.10	-3.04 %	K V

Nachrichten zu Biohaven Pharmaceutical Holding Co Ltd Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten